Quick facts (at-a-glance)

• IPO Opening Date: 9 October 2025. (Zerodha)
• IPO Closing Date: 13 October 2025. (Zerodha)
• IPO Allotment Date (tentative): 14 October 2025 (allotment), with credit/refunds on 15 October 2025. (Kotak Securities)
• IPO Listing Date (tentative): 16 October 2025. (Kotak Securities
• Price band: ₹461 – ₹485 per share. (Moneycontrol)
• Lot size: 30 shares. Minimum fund required (retail, 1 lot at upper band): ₹14,550. (Zerodha)
• Maximum lots retail can bid: Up to 13 lots (390 shares) — upper investment at upper band ≈ ₹1,89,150. (This is the usual retail maximum published in the IPO details.) (Kotak Securities)
• Total fund raise by company: ₹1,377.50 crore (Fresh issue of ₹500 Cr + Offer For Sale (OFS) ~ ₹877.5 Cr). (The Economic Times)

About Rubicon Research (short overview)

Rubicon Research Limited is an Indian pharmaceutical company focused on specialty formulations and generics — supplying mostly to regulated markets. The company has reported robust revenue and profit growth in recent years, invests heavily in R&D (a higher R&D spend compared to many peers), and has been backed by private equity (General Atlantic was a major shareholder pre-IPO). The IPO values the company in the ~₹7,500–8,000 crore range at the stated price band. (The Week)

(For a detailed look, read the company’s Draft Red Herring Prospectus on their investor page.) (Rubicon)

Key management & ownership snapshot

• Promoters & large shareholders: Promoter stake will dilute from ~78% to ~62% after the issue; General Atlantic (a private equity investor) will reduce from ~52% to ~35.8% following the OFS. (The Economic Times)
• Board / Senior management: Management details and bios are available in the RHP — refer to the company RHP for full list of directors and key executives. (Rubicon)

Major products / Business model

• Focus on pharmaceutical formulations (specialty and generic finished dosages) sold primarily to regulated markets (notably the US). The business model includes manufacturing, formulation development, and partnership/supply contracts with large global customers. (The Economic Times)

Financial snapshot & growth (summary)

• The company has shown strong revenue and profit growth over the last 2–3 years, with expanding margins and high return on net worth (RoNW cited near ~29% in recent coverage). The firm’s R&D intensity is materially higher than many peers (reported ~10.4% of revenue versus typical 2–8% for peers). Detailed historic revenue, EBITDA and PAT figures are available in the RHP — check the DRHP for line-by-line numbers before investing. (The Economic Times)

Competitors / Industry peers

• Other mid-large pharmaceutical formulation and contract manufacturers in India and internationally (peers will include speciality/generic manufacturers listed in India and global peers). Compare valuation multiples and US-market exposure when benchmarking. (See RHP industry report & analyst notes for peer tables.) (Rubicon)

What analysts and the market are saying (high level)

• Early media coverage and broker notes highlighted a healthy grey market premium (GMP) and solid interest from investors on IPO open. Analysts praise revenue growth and R&D emphasis, but flag concentration risks (heavy reliance on the US market and a few large customers). The IPO is a combination of fresh capital (company gets ₹500 Cr) and OFS (sellers receive proceeds). (mint)

Pros (Why investors may like Rubicon)

1. Strong top-line and margin expansion in recent years — demonstrates operational traction. (The Economic Times)
2. High R&D intensity, which may support niche products and better margins over time. (The Economic Times)
3. Backing by large PE investor (General Atlantic) — a validation of earlier growth and governance. (The Economic Times)

Cons / Risks (what to watch)

1. High geographical concentration: ~98% of revenue from the US market — any US regulatory, pricing or tariff shock could materially affect revenues. (The Economic Times)
2. Customer concentration: Top 5 customers contribute a large share (reported ~71% of revenue coming from those customers) — loss or pricing pressure from any large customer is a material risk. (The Economic Times)
3. Valuation: At the quoted price band the company is valued in a relatively high market-cap band (~₹7,500–8,000 Cr); you should judge valuation versus peers and growth sustainability. (The Week)
4. Partial OFS: A sizable portion (~₹877.5 Cr) is an offer-for-sale, which means selling shareholders (not the company) will pocket proceeds — this can reduce the positive cash usage impact on business growth. (The Economic Times)

IPO application practicals (how much to keep ready)

• Min (retail): 1 lot = 30 shares → ₹14,550 at the upper band (₹485). (Zerodha)
• Max (retail): Typically up to 13 lots = 390 shares → ~₹1,89,150 at upper band. (Broker pages list 13-lot cap for retail for this issue.) (Kotak Securities)

Our Recommendation — Apply or Not?

Short answer: Apply with caution — consider 1 lot if you want long-term exposure; avoid large short-term bets unless you are comfortable with concentration risks and valuation.

Why (summary):

• Good for selective long-term investors: The company shows strong growth, attractive margins and meaningful R&D investment — traits appealing for long-term pharma bets. If you believe Rubicon can sustain growth and diversify customers/geographies, a small allocation (1 lot) is reasonable for long-term holding. (The Economic Times)
• Caution for short-term listing gains / traders: The IPO carries geographic & customer concentration risk and a relatively high valuation band. Listing-day upside is possible (GMP was positive on open), but it’s speculative and tied to market sentiment. For risk-averse or short-term traders, this is not a must-apply. (mint)
• If you already hold pharma exposure: Avoid heavy overlapping positions. Consider whether adding Rubicon meaningfully diversifies your existing portfolio.